AgomAb Therapeutics NV’s USD 74 Million Series B Financing round

Deloitte Legal assisted AgomAb Therapeutics NV on the deal.

AgomAb Therapeutics NV completed the raise of a USD 74 million Series B financing round to fund a clinical proof of concept for the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth for the company’s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases.

AgomAb Therapeutics is a limited liability company, with headquarters in Ghent (Belgium), which pioneers therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Their growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes.

The Deloitte legal team was led by Christoph Michiels (Photo), and comprised team members Jan De Poorter, Vincent De Munck and Roan Asselman.

Involved fees earner: Roan Asselman – Deloitte Tax & Legal; Vincent De Munck – Deloitte Tax & Legal; Jan De Poorter – Deloitte Tax & Legal; Christoph Michiels – Deloitte Tax & Legal;

Law Firms: Deloitte Tax & Legal;

Clients: AgomAb Therapeutics NV;

Print Friendly, PDF & Email
Federica Tiefenthaler

Author: Federica Tiefenthaler